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ABSTRACT
Objective: To quantify the journeys and CO2
emissions if women with breast cancer are treated
with risk-adapted single-dose targeted intraoperative
radiotherapy (TARGIT) rather than several weeks’
course of external beam whole breast radiotherapy
(EBRT) treatment.
Setting: (1) TARGIT-A randomised clinical trial
(ISRCTN34086741) which compared TARGIT with
traditional EBRT and found similar breast cancer
control, particularly when TARGIT was given
simultaneously with lumpectomy, (2) 2 additional UK
centres offering TARGIT.
Participants: 485 UK patients (249 TARGIT, 236
EBRT) in the prepathology stratum of TARGIT-A trial
(where randomisation occurred before lumpectomy and
TARGIT was delivered simultaneously with lumpectomy)
for whom geographical data were available and 22
patients treated with TARGIT after completion of the
TARGIT-A trial in 2 additional UK breast centres.
Outcome measures: The shortest total journey
distance, time and CO2 emissions from home to
hospital to receive all the fractions of radiotherapy.
Methods: Distances, time and CO2 emissions were
calculated using Google Maps and assuming a fuel
efficiency of 40 mpg. The groups were compared using
the Student t test with unequal variance and the non-
parametric Wilcoxon rank-sum (Mann-Whitney) test.
Results: TARGIT patients travelled significantly fewer
miles: TARGIT 21 681, mean 87.1 (SE 19.1) versus
EBRT 92 591, mean 392.3 (SE 30.2); had lower CO2
emissions 24.7 kg (SE 5.4) vs 111 kg (SE 8.6) and
spent less time travelling: 3 h (SE 0.53) vs 14 h (SE
0.76), all p<0.0001. Patients treated with TARGIT in 2
hospitals in semirural locations were spared much
longer journeys (753 miles, 30 h, 215 kg CO2 per
patient).
Conclusions: The use of TARGIT intraoperative
radiotherapy for eligible patients with breast cancer
significantly reduces their journeys for treatment and
has environmental benefits. If widely available, 5
million miles (8 000 000 km) of travel, 170 000
woman-hours and 1200 tonnes of CO2 (a forest of
100 hectares) will be saved annually in the UK.
Trial registration number: ISRCTN34086741; Post-
results.
INTRODUCTION
Awareness of the impact of climate change
has led to increasing information being
Strengths and limitations of this study
▪ This study calculated journeys made by patients
with breast cancer to receive their radiotherapy,
using the geographic and treatment data from a
large randomised trial.
▪ The study then assessed the same outcomes
(travel distances, travel time and CO2 emissions)
in two semirural breast cancers—the results of
this assessment confirm and reinforce the ori-
ginal results: the benefit of the use of TARGIT
for patients from two semirural breast centres
was even larger (753 miles (1212 km), 30 h,
215 kg CO2 per patient).
▪ The carbon emissions were calculated from mea-
sured fuel economies in a standard family car in
real-world driving conditions rather than relying
on a car manufacturer’s claimed emission figures
that are derived under strict test conditions.
▪ Although the patients’ addresses and address of
the radiotherapy centre were known and used to
calculate the journey, the exact daily travel for
each patient was not available. However, this is
unlikely to affect the results. Similarly, our esti-
mates for carbon emissions assume a standard
family car, so it may not be exact.
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displayed about the carbon footprint of certain activities.
For example, we are now more aware of the concept of
‘food-miles’ and the beneﬁts of buying locally sourced
products. With increasing centralisation of resources in
healthcare, the trend is exactly the reverse of the trend
to ‘shop locally’. There is in fact a greater demand on
patients and their families to travel to receive specialist
treatment.1 2
Numerous studies have assessed the impact of travel
time and distance on a patient receiving healthcare or
choosing treatment options.3 4 In some international
studies, patients who had to travel many miles for radio-
therapy after breast cancer treatment chose a mastec-
tomy rather than breast conservation5–7 and multiple
fractions of whole breast radiotherapy, but this was not
seen in some UK studies.3 8 Similarly, the uptake of
chemotherapy or postmastectomy radiotherapy may be
lower in rural communities where travel to a radiother-
apy centre is difﬁcult.9 10 The daily travel for patients
and their relatives will often affect their quality of life
and impact on them and their family members.1 2
The management of breast cancer has changed over
the decades. However, the requirement of patients to
travel to receive these specialist services is often forgot-
ten by policymakers.11 Conventionally, patients who
have breast cancer and breast-conserving surgery are
recommended to receive whole breast external beam
radiotherapy (EBRT) daily, over 3–6 weeks following
surgery.
Current UK provision of radiotherapy within the
National Health Service (NHS) is based in 62 hospital
sites (ﬁgure 1): England—52, Scotland—5, Wales—3
and Northern Ireland—2.12 The National Radiotherapy
Advisory Group recommends that travel times should be
less than 45 min for the majority of patients as this is
known to impact on access and uptake.13 The red dots
in ﬁgure 1 show a radius of 13 miles (21 km), which is
the average distance of a patient from the radiotherapy
centre in the TARGIT-A trial, thus showing how large
areas remain outside these perimeters. Accounting for
the population density, we have estimated that two-thirds
of the UK population lives more than 13 miles from
a radiotherapy centre (ﬁgure 1 and supplementary
table 2).28
Approaches such as the use of risk-adapted targeted
intraoperative radiotherapy (TARGIT IORT)14 15 can
obviate the need for whole breast EBRT in selected
patients.16 17 Indeed, single-dose TARGIT IORT is now
offered routinely as a treatment option in many other
countries.18
The TARGIT-A trial was an international randomised
controlled trial initiated in the UK that showed that a
single dose of IORT using the Intrabeam device (Carl
Zeiss) was not inferior to traditional EBRT in local
control after breast-conserving surgery.17 This delivers a
single fraction of radiotherapy (20 gy) into the tumour
cavity and adds about 20–40 min to the operative pro-
cedure. UK centres contributed 20% of the 3451
patients recruited in the TARGIT-A trial from 33 centres
in 11 countries worldwide.
This study compares the travel implications and
journey times within each randomised treatment group
of the TARGIT-A trial in the UK.
We also measured the impact of introducing TARGIT
IORT in two UK breast centres without on-site radiother-
apy and assessed the likely environmental gains to be
made by implementing TARGIT IORT in the manage-
ment of early breast cancer in the UK.
METHODS
TARGIT-A trial data
Geographic and radiotherapy data from the UK patients
who had been recruited into the TARGIT-A randomised
controlled trial were assessed. In six UK hospitals
(University College London, Royal Free, Whittington,
Guy’s and St Thomas’ (all in London), Ninewells (in
Dundee, Scotland) and Royal Hampshire County (in
Winchester)), the patients undergoing breast-conserving
surgery either received traditional EBRT or were
selected to receive TARGIT IORT as a single dose using
the Intrabeam device (Carl Zeiss). Patients who received
TARGIT were recommended additional breast EBRT
(without a tumour bed boost) if their ﬁnal tumour hist-
ology had prespeciﬁed adverse prognostic factors.
Fifteen per cent to 20% of patients randomly allocated
to receive TARGIT were expected to receive additional
EBRT. Supported by the results of the TARGIT-A trial,17
the preferred method of using TARGIT is during initial
lumpectomy, and therefore, for this paper, we restricted
the analysis to the prepathology stratum of the
TARGIT-A trial.
For each patient, we ﬁrst calculated the shortest
driving distance from home to the radiotherapy centre
and travel time (excluding trafﬁc delays) using Google
Maps. We then calculated the total distance travelled
and total journey time to receive all of the recorded frac-
tions of radiotherapy for each patient. We assumed that
patients who received EBRT required two additional
journeys, for consent and for radiotherapy planning.
Typically, a patient receiving 15 fractions of EBRT
(3 weeks of radiotherapy) would attend the radiotherapy
centre on at least 17 occasions. Amongst patients
selected to have EBRT, those who lived a considerable
distance from a TARGIT trial centre (more than
60 miles, 100 km) were excluded from the analysis (n=7)
as they may have chosen to travel to a local radiotherapy
centre closer to their home. A comparison was made
between the aggregate distance and travel times between
the two treatment arms (TARGIT vs EBRT) and between
TARGIT-A trial centres in London, Winchester and
Dundee.
Swindon and Harlow patients
In 2014, two UK breast centres without on-site radiother-
apy units (in Swindon and Harlow) started using
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TARGIT IORT. Using the patient’s postcode and Google
Maps, the distance that each of the 22 patients would
have driven to their local radiotherapy centres (Oxford,
Bath, North Middlesex or Cambridge) was calculated.
To assess the impact of travelling to a radiotherapy
centre from his own hospital, the ﬁrst author (NJC)
undertook six return journeys from Swindon to Oxford
and from Swindon to Bath using a medium-sized family
car (a 7-year-old car with a 1.9 L diesel engine) in
normal driving conditions, during a weekday and
outside of peak times, and measured the actual distance
travelled, time taken and fuel used. The estimates using
Google maps were found to be an accurate reﬂection of
such journeys (see online supplementary table S1).
Figure 1 Map of the UK
showing the locations of
radiotherapy centres with a radius
of 13 miles (20 km) drawn around
them. Two-thirds (63%) of the UK
population live outside of towns
that have a radiotherapy centre
(data given in online
supplementary table S2).
Contains OS data © Crown
copyright 2016, and reference 28.
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Therefore, for each patient with breast cancer treated
with lumpectomy and TARGIT, we could estimate these
values for travelling between their home and the radio-
therapy centre using Google maps. We estimated the
total travel distance assuming a standard 3-week course
of radiation for the 22 patients who received TARGIT
IORT mainly as part of training for participation in the
TARGIT-B trial (http://www.nets.nihr.ac.uk/projects/
hta/1010407, http://goo.gl/sgdcTr) in the past
15 months.
Estimation of CO2 emission
We estimated the carbon dioxide produced by private
transport based on the following measurement and
assumptions: the fuel economy of the car was 39.7 miles
per gallon (mpg; 6.96l/100 km), public transport usage
was negligible, and half of the cars used diesel as a fuel
and half used petrol. The CO2 produced by a 40 mpg
diesel car is 299 g/mile (186 g/km) and that produced
by a 40 mpg petrol car is 272 g/mile (169 g/km).19
Statistical analysis
The null hypothesis was no difference in travelling dis-
tance or time between the two randomised groups. For
statistical analyses, given that the distances travelled were
skewed (not normally distributed) for at least one of the
randomisation arms (TARGIT), we used both the
Student t test with unequal variance as well as the non-
parametric Wilcoxon rank-sum (Mann-Whitney) test. We
used Microsoft Excel and STATA V.14.0 for statistical
analysis.
RESULTS
TARGIT-A trial data
Between 1999 and 2012, 714 patients were recruited to
the UK centres for the TARGIT-A trial, and of these,
568 were in the prepathology stratum. Those patients
randomised to receive TARGIT had their radiotherapy
at the time of their primary surgery. Eighty-three
patients (TARGIT 50, EBRT 33) were excluded from
analysis due to insufﬁcient (n=70) or inaccurate (n=6)
home postcode details, or where the patient would have
travelled to a closer radiotherapy centre to receive
EBRT (n=7), leaving 485 (85.4%) for data analysis. Of
these, 236 patients (48.7%) had been randomised to
receive EBRT. In the 249 patients who had been rando-
mised to receive TARGIT, 46 (18.5%) received add-
itional EBRT.
Travel distance
Overall, these 485 UK patients would have travelled
114 273 miles (183 905 km; TARGIT 21 681 (34 892 km)
versus EBRT 92 591 (149 011 km)) for planning,
consent and receiving radiotherapy as part of the
TARGIT-A trial, with those in the TARGIT arm travelling
considerably less than those in the EBRT arm (mean dis-
tance driven in miles: TARGIT 87.1 (SE 19.1) versus
EBRT 392.3 (SE 30.2), in kilometres: TARGIT 140.2
(SE 30.7) versus EBRT 631.4 (SE 48.6), p<0.0001
Wilcoxon rank-sum test, and p<0.0001 with the Student t
test assuming unequal variance). Thus, the patients in
the TARGIT arm were saved, on average, a travel dis-
tance of 305.2 miles (SE 35.8; 491.2 km (SE 57.6)). The
difference in travelling distance was more pronounced
for patients in Dundee (TARGIT 123.9 miles (SE 44.2)
vs EBRT 647.4 miles (SE 55.2), TARGIT 199.4 km (SE
71.1) vs EBRT 1041.9 km (SE 88.8)), reﬂecting its rural
surroundings where, on average, each patient saved
themselves a journey of 523.5 miles (SE 70.7), 842.5 km
(SE 113.8; ﬁgure 2 top)
CO2 emission
We estimate the total CO2 emissions by UK patients in
the prepathology stratum of the TARGIT-A trial to be
32.5 tonnes, of which 81% (26.3 tonnes) was contribu-
ted by patients in the EBRT arm. The TARGIT arm con-
tributed 19% of the total CO2 (6.2 tonnes), which
corresponds to the fact that 18.5% of these patients
received additional EBRT. The mean CO2 emissions for
each patient in the EBRT arm was 111.4 kg (SE 8.6),
whereas the mean emission by those randomised to
TARGIT was 24.7 kg (SE 5.4), p<0.0001; a reduction of
86.7 kg (SE 10.2) per patient. A much larger reduction
in emissions by being in the TARGIT arm was seen in
the patients treated in Dundee, reﬂecting the greater
Figure 2 The mean distance travelled (above) and CO2
emissions (below) per patient for the allocated treatment. The
error bars show the SE of the mean. (1 mile=1.61 km). EBRT,
external beam whole breast radiotherapy.
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distance travelled by these patients. The mean CO2 emis-
sion for Dundee patients randomised to receive TARGIT
was 35 kg (SE 12.5) compared with 184 kg (SE 15.7) for
EBRT patients, a saving of 149 kg (SE 20.1) of CO2
(ﬁgure 2 bottom).
Travel time
Overall, the mean time taken to travel for radiotherapy
was 3.0 h (SE 0.53) for those randomised to TARGIT
versus 14.0 h (SE 0.76) for EBRT, an average saving of
11 h (SE 0.92). The saving was longer for Dundee
patients, at 14.2 h (SE 1.6). This does not include time
spent in trafﬁc jams, ﬁnding a parking space, waiting for
the turn to receive the radiation dose, or actually receiv-
ing the fraction of radiotherapy. Of the 249 patients in
the TARGIT arm, 81.5% (n=203) patients had received
TARGIT IORT during lumpectomy and required no
further travel for radiotherapy. The 46 patients who
received additional EBRT travelled similar distances with
similar journey times as those receiving traditional
EBRT. Figure 3 shows the time taken to travel for radio-
therapy in the three cities. Note that although the dis-
tances in London were shorter (ﬁgure 2), the time for
travel for EBRT was relatively longer because of lower
average speeds achievable in the city.
Swindon and Harlow patients
In the past 15 months ( July 2014 to September 2015),
the ﬁrst 22 patients who received TARGIT IORT in
Swindon (n=7) and Harlow (n=15) saved, on average,
753 miles (median 717, range 129–1751 miles; 1212 km
(median 1154, range 208–2818 km)) of travel. Patients
treated in Swindon would have travelled farther for
EBRT than those in Harlow (1014 (SE 224) vs 631 (SE
130) miles per patient (1632 (SE 361) vs 1016 (SE 209)
kilometres per patient); ﬁgure 4). These 22 patients
would have driven a total distance of 16 572 miles
(26 664 km) if they had received traditional EBRT. A
total of 4.73 tonnes of CO2 would have been produced
by these car journeys (215 kg/ patient). Each Swindon
patient saved approximately 30.9 h (SE 3.3) of travelling
time with mean journey times of 1 h 50 min each day
(median 1 h 52 min, range 1 h 4 min–2 h 28 min).
Harlow patients saved 18.5 h (SE 1.9) of journey times
with mean daily return journey times of 1 h 6 min
(median 19 h, range 28 min–1 h 38 min).
DISCUSSION
We found that within the TARGIT-A trial, UK patients in
the prepathology stratum randomised to TARGIT saved
themselves from travelling 305 miles (491 km) for 11 h
and avoided CO2 emissions of 86 Kg. In the context of
routine clinical practice in two hospitals outside of
London, the saving per patient was much larger in
terms of distance: 753 miles (1212 km), CO2 emissions
—215 kg CO2 and time—between 19 and 31 h. Of
course, we have not taken into account the actual psy-
chological distress that may also be reduced.
This study is a detailed analysis of the distance trav-
elled by UK patients within a large randomised inter-
national study. Use of the patient’s postcode allowed
accurate journey distances to be calculated and, by using
UK-wide data from patients treated in four geographical
centres, this allowed for a comparison of the travel impli-
cations for patients within an urban or semirural setting.
The predicted travel times according to Google Maps
were very close to the measured index journeys taken by
the author. However, these journeys are likely to be an
underestimate of actual times taken by patients as these
cannot take into account any delays due to trafﬁc or
parking problems.
The medical literature contains few studies about the
implications for patients and their families in travelling
to receive radiotherapy. Our data are consistent with the
one UK published study that showed that some patients
were travelling up to 60 miles in each direction.1
Estimation of impact on UK patients with breast cancer
In the UK, over 50 000 new breast cancers are diagnosed
each year,20 of which approximately 75% receive breast-
conserving surgery21 22 and, depending on the deﬁn-
ition of suitability of patients for IORT as a treatment
modality (ASTRO, ESTRO or TARGIT criteria23–25),
15.8%, 34.1% or 54% of these patients could be
Figure 3 Mean time travelled by a patient for each allocated
treatment. EBRT, external beam whole breast radiotherapy.
Figure 4 Estimated travel that was saved by patients in
Swindon and Harlow because they were treated with TARGIT
IORT (1 mile=1.61 km).
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offered single-dose TARGIT IORT. If this treatment was
offered in the UK and established patient selection
criteria applied, either 5925 12 800 or 20 250 may be
saved many weeks of travel to receive EBRT. Using
the very conservative estimate of travelling distance
(provided by the TARGIT study patients), we estimate
that this could save 1.8, 3.9 or 6.2 million miles of jour-
neys and reduce UK CO2 emissions by between 516
and 1763 tonnes annually (table 1). It seems to us that
a conservative estimate is 5 million miles of journey
saved per year, that is, about 100 miles per breast
cancer case diagnosed.
It should be noted that early in the course of the
TARGIT-A trial, most UK radiotherapy departments
began to adopt the 3-week regimes rather than 6-week
regimes, so the average number of fractions of radiation
received by the trial patients was 17.5. The current provi-
sion of radiotherapy is concentrated in the larger hospi-
tals in urban centres, so patients could face either a
daily prolonged ‘cross-city commute’ or a longer journey
from surrounding towns or villages. The geographical
location of many moderate-sized UK breast centres is
such that patients need to travel considerable distances
to receive radiotherapy, and we need to remember that
the potential environmental and economic savings of
introducing TARGIT may be greater when applied to a
breast cancer population outside of large UK urban
centres.
These ﬁgures are likely to be an underestimate of the
CO2 reductions as applied in the UK, as we have not
taken into account trafﬁc conditions. Similarly, the
savings in travel times, mileage and CO2 for patients is
likely to be even greater as many UK breast units do not
have an on-site radiotherapy centre, as is the case with
two of the six TARGIT-A trial centres (Whittington and
Winchester) that required their patients to travel to a dif-
ferent hospital for EBRT. Typically, most UK patients,
just as the patients treated in Swindon or Harlow, would
thus travel more than twice the distance of their
TARGIT study counterparts (753 vs 305 miles; 1212 vs
491 km).
Carbon sequestration by woodland is often promoted
to offset carbon production. Depending on tree species,
the annual rate of carbon absorption for UK forests is 2–
5 tonnes/hectare.26 One tonne of carbon is contained
within 3.67 tonnes of CO2. Using a ﬁgure of 3 tonnes/
hectare per year, we estimate that failing to introduce
TARGIT in the UK would require continuous mainten-
ance of an area of mature forest over an area of 47–395
hectares to offset the CO2 produced by travel of these
selected patients to receive radiotherapy. This forest
would need to cover St Jame’s Park (23ha), Green Park
(19ha), Buckingham Palace Gardens (17ha),
Kensington Gardens (111Ha) and Hyde Park (142ha)
combined.
The use of public transportation or bicycles and
walking, particularly in London, may change these calcu-
lations of the carbon footprint. However, the vast major-
ity of patients in the rest of the country would have used
a car for which these calculations are valid.
As clinicians, we need to remember the impact of
our prescribed therapies on patients and their rela-
tives. In rural areas, chemotherapy services may be
provided closer to the patient’s home to reduce the
need to travel, and indeed, breast screening is usually
available using mobile units. However, the need to
travel to receive radiotherapy has an environmental
impact that, until now, has been ignored. We have
demonstrated that providing single-dose TARGIT
treatment to selected UK patients with breast cancer
will beneﬁt patient travel times and CO2 emissions.
Given that patients with breast cancer constitute about
a third of patients in a radiotherapy department, this
should also reduce the trafﬁc congestion around the
hospital.
This is the ﬁrst study to quantify the environmental
beneﬁt of introducing TARGIT IORT and demonstrates
the magnitude of the impact on our environment of
Table 1 Estimate of annual number of UK patients with breast cancer suitable for IORT, travel distances saved and
reduction in CO2 emissions (1 mile=1.61 km)
Selection criteria
Proportion
of UK
patients (%)
Annual UK
patients suitable
for TARGIT-
Alone
Travel distance saved
(million miles)
305 mile/pt* or
753 miles/pt†
CO2
emissions
saved (tonnes)
Area of forest to
sequester annual
CO2 emissions‡ (ha)
ASTRO§ 15.8 5925 1.81* 516* 46.9*
4.46† 1274† 115.7†
ESTRO§ 34.1 12 800 3.90* 1115* 101.2*
9.64† 2752† 249.9†
TARGIT¶ 54 20 250 6.18* 1763* 160.2*
15.25† 4353† 395.4†
*Estimate as per TARGIT-A trial patients.
†Estimate as per Swindon and Harlow patients.
‡Calculated using a value of three tonnes carbon sequestered per hectare per annum.§Based on consensus opinion only.23 24
¶Based on randomised evidence (TARGIT-A trial) and two large cohort studies (French and German).17 25
IORT, intraoperative radiotherapy.
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asking our patients to travel to receive centralised radio-
therapy services. The analysis and concepts described
are applicable in every aspect of healthcare where a
patient is required to travel to receive a series of treat-
ments. While the term ‘food-miles’ has become com-
monplace in the mindset of the general public,
perhaps the concept of ‘therapy-miles’ ought to be
considered when planning and prescribing patient
treatment.
Our ﬁnding of a saving of about 87 to 215 kg CO2
emissions for each patient receiving TARGIT (and thus
from making TARGIT available to every patient with
breast cancer having a lumpectomy in the NHS) is con-
siderably greater than the estimated savings of the study
investigating the beneﬁts of introducing a different
mode of improving access to services, namely, mobile
breast screening units, which is about 1.25 kg CO2 per
woman screened.27
We conclude that introducing TARGIT as an option
for appropriate patients in the UK will contribute signiﬁ-
cantly to saving patients time, cost, fuel and CO2
emissions.
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